CN110248937B - 4,5-环状1,2,4-三唑酮 - Google Patents

4,5-环状1,2,4-三唑酮 Download PDF

Info

Publication number
CN110248937B
CN110248937B CN201780067556.4A CN201780067556A CN110248937B CN 110248937 B CN110248937 B CN 110248937B CN 201780067556 A CN201780067556 A CN 201780067556A CN 110248937 B CN110248937 B CN 110248937B
Authority
CN
China
Prior art keywords
fluoro
oxo
group
triazolo
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780067556.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110248937A (zh
Inventor
S.N.格拉德尔
D.阮
K.艾斯
J.巩特尔
T.斯特菲尔德
A.詹泽
S.克里斯蒂安
T.米勒
S.埃尔谢赫
H.J.周
C.赵
D.B.赛克斯
S.J.费拉拉
K.刘
S.A.赫伯特
C.默兹
M.尼胡斯
C.F.尼辛格
M.谢弗
K.齐默尔曼
J.克纳布莱恩
K.泰德
T.福佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
General Hospital Corp
Broad Institute
Harvard University
Original Assignee
Bayer AG
Bayer Pharma AG
General Hospital Corp
Broad Institute
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG, General Hospital Corp, Broad Institute, Harvard University filed Critical Bayer AG
Priority to CN202210298141.0A priority Critical patent/CN114921391B/zh
Publication of CN110248937A publication Critical patent/CN110248937A/zh
Application granted granted Critical
Publication of CN110248937B publication Critical patent/CN110248937B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780067556.4A 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮 Active CN110248937B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210298141.0A CN114921391B (zh) 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103642 2016-10-27
CNPCT/CN2016/103642 2016-10-27
PCT/EP2017/077301 WO2018077944A2 (en) 2016-10-27 2017-10-25 4,5-annulated 1,2,4-triazolones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210298141.0A Division CN114921391B (zh) 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮

Publications (2)

Publication Number Publication Date
CN110248937A CN110248937A (zh) 2019-09-17
CN110248937B true CN110248937B (zh) 2022-03-29

Family

ID=60293935

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780067556.4A Active CN110248937B (zh) 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮
CN202210298141.0A Active CN114921391B (zh) 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210298141.0A Active CN114921391B (zh) 2016-10-27 2017-10-25 4,5-环状1,2,4-三唑酮

Country Status (8)

Country Link
US (2) US10968216B2 (cg-RX-API-DMAC10.html)
EP (1) EP3532474B1 (cg-RX-API-DMAC10.html)
JP (3) JP7680184B2 (cg-RX-API-DMAC10.html)
CN (2) CN110248937B (cg-RX-API-DMAC10.html)
CA (1) CA3041650A1 (cg-RX-API-DMAC10.html)
TW (1) TW201827430A (cg-RX-API-DMAC10.html)
UY (1) UY37460A (cg-RX-API-DMAC10.html)
WO (1) WO2018077944A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
AU2020338985A1 (en) * 2019-08-29 2022-04-14 Janssen Biotech, Inc. Substituted urea dihydroorotate dehydrogenase inhibitors
CN114630822B (zh) * 2019-10-10 2024-10-01 詹森生物科技公司 联芳基二氢乳清酸脱氢酶抑制剂
EP4166551A4 (en) * 2020-05-29 2024-07-10 Medshine Discovery Inc. Triazolone compound
JP2023535346A (ja) * 2020-07-14 2023-08-17 ナンジン ゼンシャイン ファーマシューティカルズ カンパニー リミテッド Ｄｈｏｄｈ阻害剤としての化合物
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
US20240228482A1 (en) * 2021-04-16 2024-07-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating cancer
CN117751115A (zh) * 2021-04-16 2024-03-22 热点治疗公司 化合物、组合物和治疗癌症的方法
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
CN118284603A (zh) * 2021-11-26 2024-07-02 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087579A1 (en) * 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Substituted triazolopyridines and their use as ttk inhibitors
WO2013186692A1 (en) * 2012-06-15 2013-12-19 Glenmark Pharmaceuticals S.A. TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
DE19901846A1 (de) 1999-01-19 2000-07-20 Bayer Ag Substituierte Arylheterocyclen
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
WO2002046386A2 (en) * 2000-10-30 2002-06-13 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
CA2746221A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN105441399A (zh) * 2010-12-16 2016-03-30 细胞制药有限公司 新的7β-羟基类固醇脱氢酶突变体和制备熊去氧胆酸的方法
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN105121647A (zh) * 2012-11-01 2015-12-02 不列颠哥伦比亚大学 细胞色素p450和细胞色素p450还原酶多肽、编码核酸分子及其用途
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
CN104561093A (zh) * 2014-12-25 2015-04-29 华东师范大学 一种重组人源CYP3A4/CPR/cyt b5蛋白共转染共表达的方法
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20190307728A1 (en) * 2018-04-10 2019-10-10 Bayer Pharma Aktiengesellschaft Methods of treatment with a 2,4,5-trisubstituted 1,2,4-triazolone
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087579A1 (en) * 2011-12-12 2013-06-20 Bayer Intellectual Property Gmbh Substituted triazolopyridines and their use as ttk inhibitors
WO2013186692A1 (en) * 2012-06-15 2013-12-19 Glenmark Pharmaceuticals S.A. TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite Plasmodium falciparum;Margaret A. Phillips等;《J. Med. Chem.》;20080604;第51卷(第12期);第3649-3653页 *

Also Published As

Publication number Publication date
JP2019535689A (ja) 2019-12-12
CN114921391A (zh) 2022-08-19
CN110248937A (zh) 2019-09-17
WO2018077944A2 (en) 2018-05-03
US10968216B2 (en) 2021-04-06
CN114921391B (zh) 2024-01-02
EP3532474A2 (en) 2019-09-04
UY37460A (es) 2018-05-31
JP2022130571A (ja) 2022-09-06
JP7680184B2 (ja) 2025-05-20
US11787797B2 (en) 2023-10-17
JP2024063131A (ja) 2024-05-10
TW201827430A (zh) 2018-08-01
EP3532474B1 (en) 2024-03-27
US20190375747A1 (en) 2019-12-12
US20210188846A1 (en) 2021-06-24
WO2018077944A3 (en) 2018-06-14
JP7747799B2 (ja) 2025-10-01
CA3041650A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
CN114921391B (zh) 4,5-环状1,2,4-三唑酮
CN117425657A (zh) 用于治疗与沃纳综合征recq解旋酶（wrn）抑制有关的疾病的三唑并-嘧啶类似物
US10478423B2 (en) Substituted indazole derivatives active as kinase inhibitiors
US20230062100A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN115557907A (zh) 用作dhodh抑制剂的2,4,5-三取代的1,2,4-三唑酮
CN105246896B (zh) 吡唑并吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
EA032356B1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
CN1820009A (zh) 作为激酶抑制剂的吡咯并[3,4－c]吡唑衍生物
HK1198167A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
US20240358688A1 (en) Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
CN113348165A (zh) 用于治疗过度增殖性疾病的1,2,4-三嗪-3(2h)-酮化合物
US10941136B2 (en) Quinazoline derivative or its salt and pharmaceutical composition comprising the same
RU2860383C2 (ru) Аналоги триазолопиримидина для лечения заболеваний, связанных с ингибированием хеликазы recq при синдроме вернера (wrn)
WO2020048826A1 (en) 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048829A1 (en) 3,9-diazaspiro[5.5]undecane compounds
HK40086116B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
HK40086116A (zh) 用作dhodh抑制剂的2，4，5-三取代的1，2，4-三唑酮
WO2020048831A1 (en) 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
HK40060627A (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
HK40060627B (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
HK40006139A (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant